Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Working Capital Changes (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Other Working Capital Changes for 4 consecutive years, with -$230000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 104.54% to -$230000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $253000.0, a 94.71% decrease, with the full-year FY2025 number at $253000.0, down 94.71% from a year prior.
  • Other Working Capital Changes was -$230000.0 for Q4 2025 at Day One Biopharmaceuticals, down from $52000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.1 million in Q4 2024 to a low of -$2.8 million in Q3 2022.
  • A 4-year average of $572500.0 and a median of -$97500.0 in 2023 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: soared 2321.47% in 2023, then crashed 166.35% in 2024.
  • Day One Biopharmaceuticals' Other Working Capital Changes stood at -$163000.0 in 2022, then skyrocketed by 2321.47% to $3.6 million in 2023, then soared by 39.85% to $5.1 million in 2024, then tumbled by 104.54% to -$230000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Other Working Capital Changes are -$230000.0 (Q4 2025), $52000.0 (Q3 2025), and -$175000.0 (Q2 2025).